{
  "id": "SCR-LIP-000782",
  "statement": "Comorbid fibromyalgia may be associated with further reduced quality of life and more anxiety and depression in lipedema.",
  "claim_type": "clinical_association",
  "context": {
    "population": "women with lipedema (n=354)",
    "condition": "lipedema",
    "exposure": "comorbid fibromyalgia syndrome (FMS)",
    "comparator": "lipedema without FMS",
    "outcome": "anxiety, depression, SF-12 physical and mental QoL",
    "scope": "auto-ingested from Layer 1 surveillance"
  },
  "knowledge_state": "emerging",
  "evidence_confidence": "low",
  "evidence": [
    {
      "ref": "DOI:10.1089/lrb.2023.0038",
      "stance": "supporting",
      "study_design": "cross_sectional",
      "n": null,
      "risk_of_bias": "unknown",
      "grade": "low",
      "year": 2024,
      "amato_authored": false,
      "note": "Online self-administered survey of lipedema patients reports quality of life, anxiety, and depression measures (HADS, SF-12), directly addressing the question, though stratified primarily by FMS comorbidity rather than lipedema vs controls.",
      "title": "Prevalence of Fibromyalgia Syndrome in Women with Lipedema and Its Effect on Anxiety, Depression, and Quality of Life",
      "authors": "Cagliyan Turk et al.",
      "journal": "Lymphatic Research and Biology",
      "verification": {
        "method": "dual-model",
        "verifier_model": "anthropic/claude-sonnet-4-6",
        "primary_model": "anthropic/claude-opus-4.8",
        "quote_grounded": false,
        "stance_agreed": true,
        "faithful": true,
        "verifier_stance": "supporting",
        "verdict": "verified",
        "reason": "verified by verifier; quote not verbatim-grounded. All specific numbers in the statement (354 participants, 35% FMS prevalence, anxiety scores 13.11 vs 9.87, depression scores 10.23 vs 8.26, SF-12 physical 35.37 vs 42.55, mental 35.27 vs 40",
        "date": "2026-06-10"
      },
      "quote": "The mean anxiety and depression scores of Group 1 were significantly higher compared with Group 2 (13.11 ± 4.2 vs. 9.87 ± 4.65, 10.23 ± 3.79 vs. 8.26 ± 4.15, respectively, p < 0.001). The mental and physical subgroup scores of SF-12 (35.37 ± 8.59 vs. 42.55 ± 10.15, 35.27 ± 8.49 vs. 40.38 ± 11.36, re",
      "extraction_confidence": "moderate",
      "stance_in_source_claim": "supporting",
      "finding": "In 354 women, those with fibromyalgia (35%) had higher anxiety (13.11 vs 9.87) and depression (10.23 vs 8.26) and lower SF-12 physical (35.37 vs 42.55) and mental (35.27 vs 40.38) scores (p<0.001).",
      "from_claims": [
        "SCR-LIP-000168"
      ]
    }
  ],
  "relations": [],
  "gaps": "",
  "curators": [],
  "created": "2026-11-20",
  "updated": "2026-11-20",
  "license": "CC-BY-4.0",
  "consolidated_from": [
    "SCR-LIP-000168"
  ],
  "questions_consolidated": [
    "SQ-LIP-000041"
  ],
  "provenance": {
    "method": "consolidation (R-CLM-19)",
    "store_key": "G-00227",
    "models": {
      "primary": "claude-opus-5.5 (Claude Code subagent, 1 repair round + arbitration)",
      "verifier": "claude-sonnet (Claude Code subagent, fresh context)",
      "mode": "agent"
    }
  },
  "history": [
    {
      "date": "2026-11-20",
      "event": "created_by_consolidation",
      "detail": "general proposition consolidated from SQ-LIP-000041"
    }
  ],
  "statement_pt": "A fibromialgia comórbida pode estar associada a redução adicional da qualidade de vida e a mais ansiedade e depressão no lipedema.",
  "answers_questions": [
    {
      "id": "SQ-LIP-000041",
      "role": "refines",
      "question": "How does lipedema affect health-related quality of life?",
      "url": "https://scientificclaims.org/q/SQ-LIP-000041.html"
    }
  ],
  "url": "https://scientificclaims.org/c/SCR-LIP-000782.html"
}